Antivirals are not hypothesized by this study to directly affect symptoms.
It is hypothesized that when Vedolizumab (trade name Entyvio) patients lose response due to reactivation of a pre-existing CytoMegaloVirus (CMV). The antiviral treats the CMV, and restores the response to Entyvio (and potentially other biologicals, immunosuppressants, and steroids) blocked by the virus.
This IN NO WAY suggests UC is viral in nature, or the UC directly responds to antiviral medications.
Post Edited (DBwithUC) : 8/23/2019 8:32:14 AM (GMT-6)